Ab­b­Vie's stock and next megablock­buster take hits fol­low­ing new JAK warn­ings from FDA

While the FDA’s new warn­ings on JAK in­hibitors are based on a re­view of a Pfiz­er tri­al, it’s Ab­b­Vie that may be hurt the most.

Ab­b­Vie’s stock fell by about 10% at one point Wednes­day as its prized JAK in­hibitor Rin­voq, once fore­cast to haul in $8 bil­lion an­nu­al­ly by 2025, was looped in­to new class-wide FDA warn­ings, which in­clude risks of se­ri­ous heart-re­lat­ed events, can­cer, blood clots and death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER